Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CPS1 | P31327 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19956077 | 0.84 | ESR2 (0.55) | KDM4EMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL1620598 | 0.82 | NPC1 (0.53) | GAAALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL29634819 | 0.82 | NPC1 (0.53) | GAAALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL545311 | 0.81 | SOS1 (0.46) | KDM4EMEN1KMT2ALMNAHSD17B10 | |
| SCHEMBL16855819 | 0.79 | ERN1 (0.46) | GAAALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL15014228 | 0.79 | APP (0.59) | GAAALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL14451670 | 0.79 | MIF (0.52) | ALDH1A1MAPTKMT2ASMN1; SMN2LMNA | |
| SCHEMBL254529 | 0.78 | CA12 (0.50) | GAAALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL67498 | 0.78 | ALDH1A1 (0.61) | GAAALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL29950410 | 0.78 | ALDH1A1 (0.61) | GAAALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795164-A | Method for preparing 3-phenyl/heteroaryl-6-phenoxy-8-alkylamino-imidazo [1,2-b ] pyridazine derivative | 拜耳制药股份公司 | 2017-05-31 | — | — | CN | claimed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| CN-120129678-A | Mitogen-activated protein kinase (MEK) inhibitors | 耐斯泰德医疗公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4551558-A2 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20040116418-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB | 2002-09-19 | — | — | US | disclosed |
| US-6376492-B1 | GUANIDINE DERIVATIVES | MEDIVIR AB (SE) | 2002-04-23 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| US-5654483-A | REACTING ALKOXY-SUBSTITUTED CYCLOHEXANONE WITH DIPHENYLAMINE WHILE FORMING CYCLOHEXANONE FROM ALKOXY-SUBSTITUTED PHENOL IN PRESENCE OF SURFACE-SUPPORTED HYDROGEN TRANSFER CATALYST | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-08-05 | — | — | US | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | GAA 4593/4885ALDH1A1 731/4885KDM4E 778/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | GAA 159/4885ALDH1A1 1338/4885KDM4E 2462/4885 |
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | GAA 4749/4885ALDH1A1 2176/4885KDM4E 2144/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | GAA 4871/4885ALDH1A1 3227/4885KDM4E 3329/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | GAA 4871/4885ALDH1A1 3227/4885KDM4E 3329/4885 |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | GAA 3913/4885ALDH1A1 1862/4885KDM4E 4755/4885 |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | BRAF, MAP3K1, MAP3K5 | GAA 3939/4885ALDH1A1 3364/4885KDM4E 1608/4885 |
| US-20020132794-A1 | Compounds and methods for inhibition of HIV and related viruses | POLRMT, POLM, POLR1E | GAA 332/4885ALDH1A1 2484/4885KDM4E 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.